Last reviewed · How we verify
NCT06654895: SYMON II
Multicenter Symphony IL-6 Monitoring Sepsis ICU Validation Study
trial in Sepsis, Septic Shock in 700 participants. Currently enrolling.
30 August 2026
Quick facts
| Lead sponsor | Bluejay Diagnostics, Inc. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 700 |
| Start date | 12 November 2024 |
| Primary completion | 30 August 2026 |
| Estimated completion | 30 August 2026 |
| Sites | 5 locations across United States |
Conditions studied
- Sepsis, Septic Shock — all drugs for Sepsis, Septic Shock →
Sponsor
Bluejay Diagnostics, Inc.
Who can join
22 and older, any sex, with Sepsis, Septic Shock. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to validate a pre-defined IL-6 concentration cutoff that predicts 28-day mortality in patients who are admitted or are intended to be admitted to the ICU diagnosed with sepsis or septic shock.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06654895
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sepsis, Septic Shock
Currently open trials in the same condition.
- NCT06809868 — Role of Transposable Elements in Septic Immune Aging · recruiting
Other Bluejay Diagnostics, Inc. trials
Trials by the same sponsor.
- NCT07425587 — Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study · not yet recruiting
- NCT06181604 — Multicenter Symphony IL-6 Monitoring Sepsis ICU Study · completed
- NCT05665153 — Symphony IL-6 Study in Patients at Risk of Severe Sepsis · unknown
- NCT05060250 — Symphony IL-6 Cutoff Establishment Study for Patients at Risk of Severe Sepsis Due to COVID-19 · unknown
- NCT05048927 — Symphony IL-6 Cutoff Validation Study for Patients at Risk of Severe Sepsis · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06654895 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bluejay Diagnostics, Inc.
- Last refreshed: 3 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06654895.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing